Skip to main content
PR ToolsPsychedelicsPublic Relations

Public Relations for Psychedelics: Raising Mental Health and PTSD Awareness

By June 7, 2022No Comments
mental health

The global mental health crisis is arguably one of the largest challenges that the world is facing right now, and posttraumatic stress disorder (PTSD) presents a major public health problem for which current treatments are only modestly effective. One in five Americans experiences a mental health issue in a given year. That number is one in four globally.

In recent years, there have been more and more conversations surrounding mental health – in fact, Mental Health Awareness Month is observed in May, National PTSD Awareness Month is observed in June, and National PTSD Awareness Day is June 27 – but mental health is still a major problem.

Psychedelic drugs have been recast as possible solutions to a range of mental health problems. The rapidly increasing acceptance of psychedelic treatments is creating a strong demand from therapists and patients for access to new products and therapies. A report from Research And Markets predicts that the Psychedelic Drugs market size is projected to reach $10.75 billion by 2027, from $4.75 billion in 2020.

Companies are developing medicines from psilocybin mushrooms, MDMA, ibogaine and LSD, all of which are illegal in the US, as well as ketamine, a legal anesthetic with hallucinogenic properties. With the hope to treat a wide range of conditions, including PTSD, suicide, depression, anxiety, addiction, and even Alzheimer’s disease, a growing body of research into the therapeutic use of psychedelics is delivering promising results.

Helping veterans and others overcome PTSD through psychedelic treatment is a national conversation increasingly trending upward. MDMA (3,4-Methyl​enedioxy​methamphetamine, commonly known as ecstasy) is currently in Phase 3 Clinical Trials. A recent study to test the efficacy and safety of MDMA-assisted therapy for the treatment of patients with severe PTSD has shown that 67% of the participants no longer met the diagnostic criteria for PTSD after the study.

Psilocybin, LSD, ketamine, MDMA and other psychedelics have also recently caught the attention of startups and investors as they have lucrative market potential.

As companies seek to publicize scientific findings, solidify investment opportunities and educate the public about the many benefits of psychedelics, Durée & Company – a Fort Lauderdale- and Aspen-based public relations and marketing agency – is here to serve as your communication partner.

With proven relationships with thought leaders, we are an established presence in the rapidly expanding NeuroWellness community. Contact us today or visit our NeuroWellness-specific website for more information.


About Durée & Company, Inc.
Durée & Company, Inc. is an award-winning, full-service public relations, marketing and special events firm founded in 1999. The firm has offices in Fort Lauderdale Florida, and Aspen, Colorado. Durée & Company serves the corporate, agency and nonprofit practice areas for local, national, and international clients. Services include public relationssocial mediamarketingcontent developmentadvertisingspecial eventsbrandingradio promotions and more. Durée & Company clients include well-known names in businessfashionhospitalitytravelhealth and wellnesscannabis and hemppsychedelicstechnology and cryptocurrencymarine and yachtart and culturenonprofit organizationslegal and professional services and real estate. Durée & Company is a member of PR Boutiques International™ (PRBI), an international network of boutique PR firms. To learn more, call 954-723-9350; go to; or Join the social conversation and follow Durée & Company on FacebookInstagramTwitterYouTube and LinkedIn at @DureeCoPR.


Leave a Reply